ArticleScientific reports2026
Perioperative ketorolac use and postoperative acute kidney injury in elderly patients undergoing noncardiac surgery: a retrospective cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of nonsteroidal anti-inflammatory drugs, particularly ketorolac, in elderly patients is not recommended due to concerns about acute kidney injury (AKI). However, the effect of perioperative ketorolac use on postoperative AKI in elderly patients remains uncertain. We retrospectively reviewed patients aged ≥ 60 years who underwent noncardiac surgery lasting ≥ 1 h and were hospitalized for more than 2 days after surgery between January 2011 and June 2019. The ketorolac group included patients who received intravenous ketorolac in the operating room or post-anesthesia care unit. The primary outcome was postoperative AKI, defined according to the Kidney Disease: Improving Global Outcomes criteria. Propensity score matching (PSM) at a 1:3 ratio was performed to adjust for confounders, and a logistic regression model was used to assess the association between ketorolac use and postoperative AKI. Among 27,106 patients, 2433 (9.0%) received ketorolac at a median dose of 30 mg. The incidence of AKI during the first 7 days post-operatively was 4.2% (1024/24,673) in the non-ketorolac group and 2.9% (71/2433) in the ketorolac group. Following 1:3 PSM, perioperative ketorolac use was not significantly associated with postoperative AKI (adjusted odds ratio = 0.83, 95% confidence interval: 0.63-1.07, P = 0.16). This finding was consistent in subgroup analyses by patient comorbidities and in sensitivity analyses. Perioperative ketorolac use, primarily as a single 30 mg intravenous dose, was not associated with postoperative AKI in elderly patients undergoing noncardiac surgery. This finding suggests that low-dose, short-term perioperative ketorolac is a viable option to relieve immediate postoperative pain in elderly surgical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.